Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Company intelligence / Profile preview
CVie Therapeutics
Taipei (preclinical operations after merger)[4], Taiwanwindtreetx.com ↗
- Ownership
- Private
- Development stage
- Other
01
Overview
Prior to being acquired, CVie Therapeutics advanced two lead small molecule candidates: istaroxime (a first-in-class luso-inotropic agent for acute heart failure, Phase 2b) and rostafuroxin (a precision medicine targeting hypertension in genetically defined patients, Phase 2b). Both showed signals of efficacy and improved safety compared to conventional therapies[1][2][3][4].
- Therapeutic areas
- Cardiovascular
- Modalities
- Small molecule
- Industry
- Biotech
02
Partnerships
ScinoPharm (for API supply, CMC, and R&D collaboration)[1]
Beyond the preview
Go deeper on CVie Therapeutics.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on CVie Therapeutics.